These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 33195299)

  • 1. Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab.
    Mellaza C; Henry N; Fayolle PM; Mortaza S; Subra JF; Veyradier A; Coppo P; Augusto JF
    Front Med (Lausanne); 2020; 7():549931. PubMed ID: 33195299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
    Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK;
    N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
    Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
    Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
    Hollifield AL; Arnall JR; Moore DC
    Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
    Peyvandi F; Scully M; Kremer Hovinga JA; Cataland S; Knöbl P; Wu H; Artoni A; Westwood JP; Mansouri Taleghani M; Jilma B; Callewaert F; Ulrichts H; Duby C; Tersago D;
    N Engl J Med; 2016 Feb; 374(6):511-22. PubMed ID: 26863353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, Therapy and Open Issues.
    Trisolini SM; Laganà A; Capria S
    Mediterr J Hematol Infect Dis; 2024; 16(1):e2024060. PubMed ID: 38984099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful use of a second course of caplacizumab in relapsed thrombotic thrombocytopenic purpura.
    Shaffer J; Grove A
    Platelets; 2022 Jul; 33(5):790-791. PubMed ID: 34565299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caplacizumab as an add-on therapy in a 7-year-old girl with exacerbated immune-mediated thrombotic thrombocytopenic purpura, a case report and literature review.
    Chavaz L; Cimasoni L; Kremer Hovinga JA; Coppo P; Ansari M
    Front Pediatr; 2024; 12():1448801. PubMed ID: 39233868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Diagnosis and treatment of thrombotic thrombocytopenic purpura].
    Kubo M; Matsumoto M
    Rinsho Ketsueki; 2020; 61(5):529-535. PubMed ID: 32507820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
    Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
    J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Two Cases of Pediatric Thrombotic Thrombocytopenic Purpura Treated With Combined Therapy.
    Tripiciano C; Zangari P; Montanari M; Leone G; Massella L; Garaboldi L; Massoud M; Lancellotti S; Strocchio L; Manno EC; Palma P; Corsetti T; Luciani M
    Front Pediatr; 2021; 9():743206. PubMed ID: 34796152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience.
    Tse B; Buchholz M; Pavenski K
    Platelets; 2023 Dec; 34(1):2157807. PubMed ID: 36636834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
    Goshua G; Sinha P; Hendrickson JE; Tormey C; Bendapudi PK; Lee AI
    Blood; 2021 Feb; 137(7):969-976. PubMed ID: 33280030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Rare Case of Severe Manifestation of COVID-19 Infection Presenting as Immune-Related Thrombotic Thrombocytopenic Purpura With Multiorgan Involvement Treated With Plasmapheresis, Steroids, Rituximab, and Caplacizumab.
    Mandyam S; Fatmi SS; Banzon G; Kaur P; Katamreddy Y; Parghi D; Farooq A; Liaqat H; Basarakodu K
    Cureus; 2022 Jul; 14(7):e26961. PubMed ID: 35989829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab.
    Chung C
    Ann Pharmacother; 2021 Mar; 55(3):330-343. PubMed ID: 32715723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management.
    Sukumar S; Lämmle B; Cataland SR
    J Clin Med; 2021 Feb; 10(3):. PubMed ID: 33540569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial).
    Estcourt LJ
    Transfus Med; 2019 Jun; 29(3):146-148. PubMed ID: 31318128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How Should Complicated Cases of Thrombotic Thrombocytopenic Purpura With Positive Coombs Test Be Treated?
    Ghrewati M; Mahmoud A; Beliani T; Zakharia K; Kumar M
    Cureus; 2023 Dec; 15(12):e50742. PubMed ID: 38234934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caplacizumab in pediatric immune thrombotic thrombocytopenic purpura: the UK TTP Registry experience.
    Taylor A; Keogh L; Dickens E; Dutt T; Grainger J; Gregory R; Mapplebeck C; Richards M; Stokley S; Salta S; Taylor T; Scully M
    Blood Adv; 2024 Sep; 8(17):4563-4567. PubMed ID: 38968147
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.